A conversation about autoimmune diseases and why biotechs don't pay a dividend, because this is where the money is.

Hey Fool's health care analyst Michael Douglas here with our health care contributor Todd

Campbell all the way from New Hampshire. Todd how's it going? It's going well I'm

I'm getting really excited about the apple pie tomorrow about you. a blueberry and coconut cream, I think,

is what's really high on my list.

And as we discussed beforehand,

will probably be my breakfast the next morning.

And if I can make it happen the morning after.

So I guess Thanksgiving hacks for everyone to get the maximum amount of sugar and bad food.

Definitely looking forward to that.

Hope everyone, by the way, has a fantastic Thanksgiving.

All right, but we've got, we've got, before that, before we can have our desserts,

let's get into some important investing stuff.

We're going to start off with a conversation about

an autoimmune disease drug called Stolara.

But before we get into that I want to sort of talk a little bit about what the problems and pitfalls for a drug are.

So when you have a drug that comes, that is being tested,

you know, the first question is safety, right?

Is the drug safe? Because if it causes liver failure or heart

attacks, you know, chances are pretty good it's not going to be approved. The second thing is, does

it actually work? So when we look at a lot of Alzheimer's disease drugs that have been some of the base inhibitors that have come out in the last few years, they have just not been effective.

They've been perfectly safe, but not effective.

...